Compounded Tirzepatide After the Shortage Era: The Legal Landscape in Mid-2026

Tirzepatide — the dual GLP-1/GIP agonist marketed as Zepbound (weight management) and Mounjaro (type 2 diabetes) — came off the FDA drug shortage list on October 2, 2024. That was twenty-one months ago. The legal and regulatory landscape for compounded tirzepatide has shifted dramatically since then, and mid-2026 is a good moment to take stock of where things stand.

The Current Legal Framework

503A Pharmacies: Still Operating

Section 503A of the Federal Food, Drug, and Cosmetic Act allows traditional compounding pharmacies to prepare patient-specific prescriptions from bulk drug substances when certain conditions are met. The shortage-list removal did not eliminate 503A compounding authority. Pharmacies operating under 503A can still compound tirzepatide pursuant to individual patient prescriptions, provided they meet all 503A requirements: a valid patient-specific prescription, a bona fide prescriber-patient relationship, and compliance with state pharmacy law.

This is the pathway through which most telehealth providers currently offer compounded tirzepatide. It's legally distinct from the shortage-based compounding that occurred from 2022 to 2024, and it does not depend on the FDA's shortage-list status.

503B Outsourcing Facilities: Shut Out

Outsourcing facilities operating under 503B can only compound from bulk drug substances if the drug is on the 503B Bulks List (meaning FDA found a "clinical need") or the drug is on the active shortage list. Tirzepatide is on neither. The FDA's April 2026 proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List would formalize this prohibition — but the practical effect is already in place.

The "Essentially a Copy" Question

One of the 503A conditions that has drawn FDA enforcement attention is the requirement that compounded drugs not be "essentially a copy" of a commercially available drug. The FDA has argued that compounded semaglutide and tirzepatide are essentially copies of Wegovy/Ozempic and Zepbound/Mounjaro, respectively — and that 503A pharmacies should therefore not be compounding them.

Compounders counter that their preparations are not copies because they differ in concentration, formulation, preservative system, or delivery format from the brand-name products. This legal question has not been definitively resolved by the courts, and its interpretation varies by jurisdiction and context.

The Litigation Landscape

Multiple lawsuits have shaped the compounding landscape since the shortage-list removals:

• Outsourcing Facilities Association (OFA) v. FDA: OFA challenged the FDA's process for removing semaglutide from the shortage list, arguing the agency used flawed criteria. Federal courts denied OFA's motions for preliminary injunctions in late 2024 and early 2025, ruling that the FDA's shortage-list determinations fell within its regulatory discretion.
• Eli Lilly v. Compounding Pharmacies: Lilly has pursued legal actions against specific compounders and marketers of compounded tirzepatide, alleging trademark infringement and consumer confusion. These cases target individual actors rather than the compounding industry broadly.
• State-level enforcement: Some state boards of pharmacy have issued guidance or taken enforcement actions regarding compounding of drugs that are no longer in shortage. The outcomes vary by state, reflecting different interpretations of 503A's scope.

What the FDA Is Actually Enforcing

The FDA's enforcement actions since the shortage-list removals have focused on specific categories of bad actors rather than blanket prohibition of 503A compounding:

• Unlicensed sellers: Entities selling "compounded" tirzepatide without pharmacy licenses, prescriptions, or legitimate prescriber relationships.
• Warning-letter recipients: Pharmacies cited for manufacturing deficiencies, misbranding, or false claims about their compounded products.
• Marketing violations: Compounders using brand names (Mounjaro, Zepbound) in marketing materials, creating consumer confusion about the source and regulatory status of their products.

The FDA has not, as of mid-2026, pursued enforcement actions against compliant 503A pharmacies that compound patient-specific tirzepatide prescriptions without brand-name marketing claims and with proper pharmacy infrastructure.

The Pricing Effect

Compounded tirzepatide currently costs between $199 and $500 per month from most telehealth platforms. Brand-name Zepbound lists at approximately $1,059 per month, though Eli Lilly's savings programs, insurance coverage, and LillyDirect can reduce the out-of-pocket cost significantly for some patients.

The price gap remains the primary driver of demand for compounded tirzepatide. As long as brand-name tirzepatide costs significantly more than compounded alternatives, patient demand for compounding will persist regardless of the regulatory environment.

What Could Change

Several developments could alter the landscape in the next 6-18 months:

• FDA final rule on the 503B Bulks List: Expected between early and late 2027. If finalized as proposed, it permanently closes the 503B pathway but does not directly affect 503A.
• "Essentially a copy" litigation: A federal court ruling specifically addressing whether compounded tirzepatide qualifies as an essentially identical copy of Zepbound could narrow or confirm the 503A pathway.
• Biosimilar approvals: Tirzepatide biosimilars are years away from the U.S. market (the earliest patent expirations extend past 2030), but their eventual arrival would reshape the pricing argument for compounding.
• Congressional action: Several bills have been introduced addressing compounding access and drug pricing. Their fate depends on political dynamics that are difficult to predict.

Providers Offering Tirzepatide Through 503A Pathways